The effects of three volatile anesthetics (isoflurane, enflurane, and halothane) on basal release of glutamate and GABA from isolated rat cerebrocortical nerve terminals (synaptosomes) were compared using a dual isotope superfusion method. Concentration-dependent effects on basal release differed between anesthetics and transmitters. Over a range of clinical concentrations (0.5-2ϫ minimum alveolar concentration), basal glutamate release was inhibited by all three anesthetics, whereas basal GABA release was enhanced (isoflurane) or unaffected (enflurane and halothane). These effects may represent a balance of stimulatory and inhibitory mechanisms between transmitters and anesthetics. There were no significant differences between anesthetic effects on basal release in the absence or presence of external Ca 2ϩ , whereas intracellular Ca 2ϩ buffering limited volatile anesthetic inhibition of basal glutamate release. Although these results demonstrate fundamental differences in anesthetic effects on basal release between glutamatergic and GABAergic nerve terminals, all three volatile anesthetics at clinical concentrations consistently reduced the ratio of basal glutamate to GABA release. These actions may contribute to the net depression of glutamatergic excitation and potentiation of GABAergic inhibition characteristic of general anesthesia.
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Depression of neuronal activity by general anesthetics involves reduced excitatory glutamatergic neurotransmission and enhanced inhibitory GABAergic neurotransmission involving a number of potential molecular targets . Volatile anesthetics modulate synaptic transmission by both presynaptic and postsynaptic mechanisms (MacIver, 1997) . Anesthetic effects on basal and evoked glutamate versus GABA release together with potentiation of postsynaptic GABA A receptors (Jones et al., 1992; MacIver, 1997) likely converge to produce CNS depression by reducing excitatory and enhancing inhibitory transmission.
Presynaptic action potentials trigger neurotransmitter release via activation of voltage-gated Ca 2ϩ channels coupled to Ca 2ϩ -dependent exocytotic mechanisms (Sü dhof, 2004) . Spontaneous vesicular fusion and nonvesicular reverse transporter operation can also release neurotransmitters in the absence of depolarization-evoked Ca 2ϩ influx (Sü dhof, 2004; Cavelier et al., 2005) . These modes of action potentialindependent basal release employ distinct presynaptic mechanisms and are thought to be differentially regulated (Engelman and MacDermott, 2004) . Action potential-independent vesicular transmitter release occurs in a random, unsynchronized manner by the spontaneous fusion of vesicles to the presynaptic membrane (Engelman and MacDermott, 2004) . This spontaneous quantal release of glutamate and GABA produces miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs), respectively (Haseneder et al., 2004) and is subject to modulation by various Ca 2ϩ -dependent and Ca 2ϩ -independent mechanisms (Bouron, 2001) . Volatile anesthetic-induced increases in the frequency of mIPSCs in rat hippocampal slices have been attributed to anesthetic-induced increases in spontaneous GABA release (Nishikawa and MacIver, 2000; Nishikawa and MacIver, 2001 ). In contrast, mEPSC frequency is reduced by volatile anesthetics in rat hippocampal (Nishikawa and MacIver, 2000) and spinal cord slices (Cheng and Kendig, 2003; Haseneder et al., 2004) . Halothane decreases both mEPSC and mIPSC frequency in cultured rat cortical neurons (Kitamura et al., 2003) , suggesting regional heterogeneity in presynaptic effects. Thus, volatile anesthetics can modulate the spontaneous release of the primary excitatory and inhibitory neurotransmitters, although the effects of specific agents and their mechanisms are unclear.
Volatile general anesthetics have been reported previously to have small effects on basal release of glutamate from isolated nerve terminals (synaptosomes) (Hirose et al., 1992; Miao et al., 1995; Schlame and Hemmings, 1995; Westphalen and Hemmings, 2003a) and tissue slices (Bickler et al., 1995; Toner et al., 2001 ) and of GABA from synaptosomes (Hirose et al., 1992; Mantz et al., 1995; Westphalen and Hemmings, 2003a) , which were considered as insignificant. However, even small changes in basal transmitter release may have significant effects on CNS function (Cavelier et al., 2005) . Therefore, we attempted to better define these presynaptic effects by comparing the actions of several volatile anesthetics on basal (spontaneous) glutamate and GABA release from the same isolated rat cortical nerve terminal preparations, the results from which revealed agent-and transmitterspecific effects. (Westphalen and Hemmings, 2003a) , with the exception that reduction of cytoplasmic L-[ 3 H]glutamate with D-aspartate was not performed. In brief, the cerebral cortex of adult male Sprague-Dawley rats (200 -280 g) was homogenized in ice-cold 0.32 M sucrose with a motor-driven (500 rpm) Teflon glass homogenizer and centrifuged for 2 min at 4000g. The resulting supernatant was demyelinated by centrifugation though a sucrose gradient. The final pellet containing isolated cerebrocortical nerve terminals was resuspended in ice-cold 0.32 M sucrose and incubated with 8 nM L-[ 3 H]glutamate and 440 nM [ 14 C]GABA for 15 min at 30°C in Krebs-HEPES buffer (KHB; composition consists of 140 mM NaCl, 5 mM KCl, 20 mM HEPES, 1 mM MgCl 2 , 1.2 mM Na 2 HPO 4 , 5 mM NaHCO 3 , 0.1 mM EGTA, and 10 mM D-glucose, pH 7.4 with NaOH). Incubation was terminated by centrifugation for 10 min at 20,000g at 4°C, and prelabeled synaptosomes were resuspended in ice-cold 0.32 M sucrose.
Materials and Methods

Materials
Basal Glutamate and GABA Release. Prelabeled synaptosomes (0.3-0.8 mg of protein) were confined between Whatman GF/B glass fiber filter disks (Maidstone, UK) and superfused at 0.5 ml/min with KHB at 37°C using a customized (Scheme 1) SF12 superfusion apparatus (Brandel Inc., Gaithersburg, MD) set to collect 1-min fractions. Unless otherwise stated, anesthetics were applied for 6 min in the absence or presence of Ca 2ϩ (final free [Ca 2ϩ ] of 1.9 mM). Each experiment included the determination of evoked release (2 min pulse of 4AP in the presence of 1.9 mM Ca 2ϩ ) for interassay data normalization to control for variations in synaptosome preparation. At the end of each experiment, synaptosomes were lysed with 0.2 M perchloric acid, and residual radioactivity in the synaptosomes and each fraction was quantified by liquid scintillation spectrometry with dual isotope quench correction (LS 6000IC; Beckman Coulter, Fullerton, CA) using BioSafe II scintillation cocktail (RPI, Mt. Prospect, IL). The accuracy of the dual radiolabel assay has been verified previously in detecting changes in the release of each amino acid independently of the other (Westphalen and Hemmings, 2003b) .
Application of Anesthetics. Anesthetics were prepared by dilution of saturated solutions (isoflurane, 11.5 mM; enflurane, 11.0 mM; and halothane, 16.5 mM) in KHB and introduced through Teflon tubing from glass syringes (closed system; see Scheme 1) as a 6-min pulse. In experiments that included BAPTA-AM, preloaded synaptosomes were perfused with 50 M BAPTA-AM in KHB for 12 min at 37°C before anesthetic application. After each experiment, remaining solutions from each syringe containing anesthetic were drawn through the perfusion system and sampled upon immediate exit from the synaptosome chamber into a gas tight glass syringe and then extracted into n-heptane (1:10, v/v) for analysis by gas chromatography (Ratnakumari and Hemmings, 1998) . Solution anesthetic concentrations were compared with their potencies as defined by minimum alveolar concentration (MAC) in rat: 0.35 mM for isoflurane, 0.75 mM enflurane, and 0.35 mM halothane (Taheri et al., 1991) .
Analysis of Lactate Dehydrogenase Release. Prelabeled synaptosomes were exposed to 2-min pulses of high [K ϩ ] (20 mM KCl replacing equivalent NaCl), a K ϩ channel blocker (1 mM 4AP), or to H 2 O for 1 min using the perfusion technique described above at a flow rate of 0.2 ml/min. Anesthetic effects were examined using 6-min pulses of 2, 4, and 8ϫ MAC of isoflurane, enflurane, or halothane (Taheri et al., 1991) . Perfusate was collected in one 20-min fraction (encompassing the entire release pulse) followed by a 20-min fraction collecting remaining synaptosomal contents after lysis with H 2 O. Radioactivity was quantified as above, and lactate dehydrogenase (LDH) activity was determined by spectrophotometric measurement at 340 nm of NADH (0.5 mM) oxidation in the presence of excess pyruvate (50 mM) at 37°C for 60 min in 96-well microtiter plates using a plate reader (SoftMax Pro version 4.0; Molecular Devices, Sunnyvale CA).
Data Analysis. Release in each fraction was expressed as a fraction of synaptosomal content of labeled transmitter prior to each fraction collected. The magnitude of the release pulse was determined by subtracting baseline release (average of basal release beScheme 1. Closed superfusion system for use with volatile anesthetics. Anesthetics are contained in separate valved glass syringes. Paired syringes allow the superfusate to be switched between control perfusion buffer and volatile anesthetics alone (effects on basal release; this study) and/or preincubation before exposure to anesthetic with secretogogue (effects on 4AP-evoked release; Westphalen and Hemmings, 2005 
Release from single fraction experiments (transmitter versus LDH) was calculated as more (enhanced) or less (inhibited) than control basal release. The relationship between transmitter release and LDH release was determined by paired Student's t test after effective pairing was tested by the Pearson correlation coefficient (r). Significant correlations between anesthetic concentration and basal transmitter release were determined by linear regression analysis after establishing linearity using a Runs test. Statistical comparisons were made using Prism software, version 4.0. (Fig. 1,  right panels) .
Results
Basal
Specificity of Release. Release of the intracellular enzyme LDH is a useful indicator of the loss of membrane integrity and is commonly used to determine neurotoxicity in vitro (McKarns et al., 1997) . We compared the increase in basal transmitter release resulting from exposure to high anesthetic concentrations with the release of LDH to rule out nonspecific nerve-terminal damage. As a negative control, 2-min pulses of 4AP-evoked L- Because lytic release is not transmitter-selective ( Fig. 2A ), concurrent [
14 C]GABA release and LDH release were compared with determine whether transmitter released by high anesthetic concentrations involved nonspecific nerve-terminal membrane disruption. Isoflurane-evoked [ 14 C]GABA and LDH release was significantly different (P Ͻ 0.001; Fig. 2B 14 C]GABA from preloaded rat cortical synaptosomes were tested in the absence or presence of 1.9 mM Ca 2ϩ . Sum ⌬FR values from 6-min pulses of anesthetic or tetrodotoxin, standardized to 1 mM 4AP-evoked release in the presence of 1.9 mM Ca 2ϩ , were fitted to a rational function (see Materials and Methods for eq. 1) and shown to be Ca 2ϩ -independent. The dotted lines represent the fitted curve to combined data in the absence and presence of Ca 2ϩ . Shaded area highlights the clinical concentration range (0.5-2ϫ MAC). Linear regression analyses of data between 0.5 and 2ϫ MAC in the absence and presence of Ca 2ϩ showed significant linearity (nonsignificant nonlinearity) for all groups (right panels 3 H]glutamate after pulses of anesthetic was higher than the preanesthetic baseline for isoflurane (P Ͻ 0.0001), enflurane (P ϭ 0.0002), and halothane (P Ͻ 0.0001). This difference between preanesthetic and postanesthetic baseline release was also evident in the presence of BAPTA-AM, although the magnitude was significantly less for isoflurane (P ϭ 0.014), enflurane (P ϭ 0.028), and halothane (P ϭ 0.031). This suggests persistent internal Ca 2ϩ -dependent effects on L-[ 3 H]glutamate release by anesthetics. The effects of pulse application of all three anesthetics on basal [
14 C]GABA release were unaffected by BAPTA-AM (Fig. 3) . Internal Ca 2ϩ chelation by BAPTA-AM did not alter the overall profile of anesthetic effects on basal L-[ 3 H]glutamate and [ 14 C]GABA release between pulse and continuous application (Fig. 3) .
Pulse versus Continuous Application. Effects of pulseapplied volatile anesthetics at concentrations that produced maximal glutamate release inhibition and significant GABA release stimulation were compared with effects produced by continuously applied anesthetic. Enflurane (Fig. 3B) and halothane (Fig. 3C) produced inhibition followed by delayed increases in basal release of L-[ 3 H]glutamate above control levels after discontinuation of the pulse. Continuous application of isoflurane produced transient stimulation of basal glutamate release (Fig. 3A) , whereas continuous application of enflurane (Fig. 3B) or halothane (Fig. 3C ) produced sustained inhibition. Stimulation of [
14 C]GABA release by isoflurane returned toward control values after the pulse application. Equivalent MAC concentrations of enflurane applied as a pulse stimulated [
14 C]GABA release but not to the extent as isoflurane, whereas halothane had no effect. When continuously applied, enflurane produced sustained stimulation of [ 14 C]GABA release, whereas halothane had no effect.
Discussion
The halogenated ethers isoflurane and enflurane and the halogenated alkane halothane differentially affected basal glutamate and GABA release from isolated rat cortical nerve terminals. Effects on basal glutamate release were biphasic and agent-specific. Basal glutamate release was inhibited in the clinical concentration range (0.5-2ϫ MAC) to a degree that varied between anesthetics. This inhibition was followed by enhancement (isoflurane) or reduced inhibition (enflurane and halothane) as anesthetic concentrations increased above clinical concentrations. In contrast, basal GABA release was enhanced by isoflurane at clinical concentrations and by enflurane and halothane at supraclinical concentrations. Despite these agent-specific effects, there was a consistent trend toward a concentration-dependent net decrease in basal glutamate relative to GABA release over clinical concentrations.
Concentrations of isoflurane (up to 8ϫ MAC) and enflurane (up to 4ϫ MAC) enhanced transmitter release but did not corelease LDH, an indicator of membrane lysis. This suggests that the divergent and biphasic effects of volatile anesthetics on basal glutamate versus GABA release are pharmacological effects rather than nonspecific toxic effects. The distinct effects of anesthetics on glutamate versus GABA release support transmitter-specific sites of action on presynaptic release mechanisms, whereas the biphasic nature of these effects indicates both inhibitory and stimulatory targets associated with each transmitter. Effects on nerve-terminal glutamate and GABA transporters resulting in reverse transport are probably not the anesthetic mechanism responsible, because maximal inhibition of synaptosomal GABA uptake is Ͻ20% (Westphalen and Hemmings, 2003b) , whereas similar isoflurane concentrations produced expo- ]GABA release and LDH release is shown in response to 2-min pulses of 4AP (n ϭ 8) or 20 mM K ϩ (n ϭ 7) or a 1-min pulse of H 2 O (n ϭ 7) (A) or 6-min pulses of ϳ2, ϳ4, or ϳ8ϫ MAC of isoflurane (0.75 Ϯ 0.02 mM, n ϭ 4; 1.52 Ϯ 0.01 mM, n ϭ 4; 2.91 Ϯ 0.09 mM, n ϭ 10) (B), enflurane (1.58 Ϯ 0.03 mM, n ϭ 5; 3.22 Ϯ 0.04 mM, n ϭ 4; 6.44 Ϯ 0.11 mM, n ϭ 9) (C), or halothane (0.70 Ϯ 0.09 mM, n ϭ 4; 1.33 Ϯ 0.02 mM, n ϭ 5; 2.78 Ϯ 0.11 mM, n ϭ 10) (D). ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.0005 by paired Student's t tests.
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Westphalen and Hemmings at ASPET Journals on July 8, 2017 jpet.aspetjournals.org nential release and carrier-mediated release is unaffected by 1 mM isoflurane (Westphalen and Hemmings, 2003b) .
Preferential depression of basal glutamate over GABA release suggests fundamental physiological differences between glutamatergic and GABAergic nerve terminals. The physiological difference(s) between glutamatergic and GABAergic nerve terminals that underlie their distinct responses to volatile anesthetics remains to be determined. Although nerve-terminal Na ϩ channels are inhibited by volatile anesthetics (Ratnakumari et al., 2000) and Na ϩ channel block differentially affects evoked glutamate versus GABA release (Prakriya and Mennerick, 2000; Westphalen and Fig. 3 . Effects of pulse versus continuous application of volatile anesthetics on transmitter release. A 6-min pulse (P) or continuous (C) application of isoflurane (P: 1.45 Ϯ 0.03 mM, n ϭ 13; C: 1.49 Ϯ 0.03 mM, n ϭ 7) (A), enflurane (P: 3.33 Ϯ 0.08 mM, n ϭ 11; C: 3.01 Ϯ 0.15 mM, n ϭ 8) (B), or halothane (P: 1.57 Ϯ 0.04 mM, n ϭ 11; C: 1.44 Ϯ 0.07 mM, n ϭ 7) (C) was tested on basal release of L-[ 3 H]glutamate and [ 14 C]GABA from rat cortical synaptosomes. Effects were compared with basal release from synaptosomes loaded with 50 M BAPTA-AM using pulse and continuous perfusion of isoflurane (P: 1.45 Ϯ 0.05 mM, n ϭ 9; C: 1.48 Ϯ 0.02 mM, n ϭ 5) (A), enflurane (P: 3.27 Ϯ 0.17 mM, n ϭ 10; C: 2.95 Ϯ 0.13 mM, n ϭ 6) (B), or halothane (P: 1.58 Ϯ 0.05 mM, n ϭ 10; C: 1.47 Ϯ 0.11 mM, n ϭ 6) (C). Baseline release before pulse and continuous anesthetic application (first four to five fractions) was normalized.
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at ASPET Journals on July 8, 2017 jpet.aspetjournals.org Downloaded from Hemmings, 2003a , the selective Na ϩ channel blocker tetrodotoxin did not discriminate between basal release of both glutamate and GABA. The small effect of tetrodotoxin on basal release may reflect suppression of spontaneous action potential-evoked release or hyperpolarization of the isolated nerve terminals.
In addition to their inhibitory effects on Na ϩ channels, volatile anesthetics can also affect K ϩ and Ca 2ϩ channels (see Topf et al., 2003) , ligand-gated ion channels (Franks and Lieb, 1994) , cell signaling machinery, such as protein kinase C (Hemmings and Adamo, 1998) and G protein-coupled receptors (Yamakura et al., 2001) , and synaptic vesicle docking machinery (Hawasli et al., 2004) , all of which can modulate spontaneous transmitter release (Engelman and MacDermott, 2004) . Distinct distributions of presynaptic ion channels occur within and between neurons. Nerve-terminal-specific differences in the expression of various subtypes of Na ϩ channels (Goldin, 2001) , K ϩ channels (Veh et al., 1995) , and Ca 2ϩ channels (Reid et al., 2003) provide potential neurochemical substrates for differential pharmacological effects on glutamate versus GABA transmission through release modulation by a single agent. A major role for Na ϩ or Ca 2ϩ channels in anesthetic effects on basal release is unlikely given the low sensitivity of basal release to tetrodotoxin or Ca 2ϩ chelation. A role for the activation of K ϩ channels, including two-pore domain K ϩ channels, some of which are sensitive to volatile anesthetics (Franks and Honoré, 2004) , is possible. Augmentation of Ca 2ϩ -independent basal GABA release by volatile anesthetics, despite concurrent inhibition of presynaptic Na ϩ channels and possibly K ϩ channel activation, suggests actions at additional presynaptic sites that are specific to GABA terminals and downstream or distinct from the Ca 2ϩ -dependent step(s) of vesicular transmitter exocytosis. The bidirectional nature of isoflurane effects on basal transmitter release may involve a cumulative balance between opposing stimulatory and inhibitory mechanisms that varies between transmitter type and anesthetic agents. The observed changes in basal release suggest a net increase in basal inhibitory versus excitatory transmitter release, which may represent a component of the mechanism(s) by which volatile anesthetics depress global CNS function.
Although spontaneous fusion of synaptic vesicles can occur in the absence of extracellular Ca 2ϩ (Bouron, 2001) , the resulting miniature postsynaptic potentials are sensitive to small changes in presynaptic Ca 2ϩ concentrations by activation of voltage-gated Ca 2ϩ channels, Ca 2ϩ -permeable ionotropic receptors, and release of Ca 2ϩ from intracellular stores (Angleson and Betz, 2001) . Volatile anesthetics can inhibit multiple voltage-gated Ca 2ϩ channels (Study, 1994) and Nmethyl-D-aspartate receptors (Nishikawa and MacIver, 2000) . However, the release of basal glutamate and GABA was Ca 2ϩ -independent, ruling out significant effects at these potential targets. Volatile anesthetics may also release Ca 2ϩ from intracellular stores in neuronal cells (Mody et al., 1991) , an effect that may also occur in specific nerve terminals. This could lead to preferential increase in basal GABA over glutamate release, as suggested by the greater sensitivity of GABA release to intracellular Ca 2ϩ chelation compared with glutamate release. However, anesthetic effects on basal GABA release were essentially unchanged by external and internal calcium chelation with EGTA and BAPTA-AM, respectively. BAPTA-AM reduced the inhibition of basal glutamate release by enflurane or halothane, suggesting a role of intracellular Ca 2ϩ in the depression of basal glutamate release. Enhanced stimulation of glutamate release by isoflurane in the presence of BAPTA-AM also supports this notion, with a resulting shift in the balance between stimulatory and inhibitory effects at the glutamatergic terminal.
Anesthetics applied continuously showed sustained effects on basal glutamate and GABA release, whereas pulse applications showed transient effects that included persistent increases in glutamate but not GABA release upon termination of the anesthetic pulse. This comparison again demonstrates transmitter-selective anesthetic effects, but with a caveat that supraclinical concentrations used here may recruit additional target sites. Anesthetic was not detectable within the synaptosome chamber Ͼ8 min after cessation of pulse application (Westphalen and Hemmings, 2003a) when basal glutamate release was significantly elevated. This indicates selective and persistent changes in the glutamate release machinery after a brief anesthetic exposure. This effect on basal glutamate release was partially dependent on internal Ca 2ϩ . Persistent and preferential effects that last beyond anesthetic exposure (this study; Kapinya et al., 2002; Culley et al., 2004 ) may underlie transient excitatory and/or sustained cognitive effects of anesthesia seen clinically (Monk et al., 2005) .
In conclusion, volatile anesthetics differentially alter basal release of the major inhibitory (GABA) and excitatory (glutamate) amino acid neurotransmitters to increase the ratio of GABA to glutamate release. Preferential anesthetic inhibition of evoked (Westphalen and Hemmings, 2005) and basal (this study) glutamate release compared with GABA release combined with postsynaptic GABA A receptor potentiation (Jones et al., 1992) likely synergizes to reduce overall glutamatergic excitatory neurotransmission and potentiates GABAergic inhibitory transmission in the CNS.
